- Clearmind Medicine ( NASDAQ: CMND ) said on Wednesday it had been granted a patent from the United States Patent and Trademark Office for the use of its psychoactive compound 5-methoxy-2-aminoindane ( OTC:MEAI ) as an alcoholic beverage substitute.
- The patent follows the appointment of former Red Bull Canada executive Nicholas Kadysh as special advisor on the regulatory development of MEAI.
- Clearmind has been granted patent for MEAI-based alcohol substitute in Europe and India.
For further details see:
Clearmind medicine granted U.S. patent for psychedelic drug to treat alcoholism